NDM-9 resistance to taniborbactam

Affiliations

¹ Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
² Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Dr Risch Laboratory, Liebefeld, Switzerland.
³ Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Division of Clinical Laboratories, Fribourg Hospital, Fribourg, Switzerland.
⁴ Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland; Institute for Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁵ Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland. Electronic address: laurent.poirel@unifr.ch.

Christophe Le Terrier et al. Lancet Infect Dis. 2023 Apr.

. 2023 Apr;23(4):401-402.

doi: 10.1016/S1473-3099(23)00069-5. Epub 2023 Feb 13.

¹ Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
² Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Dr Risch Laboratory, Liebefeld, Switzerland.
³ Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Division of Clinical Laboratories, Fribourg Hospital, Fribourg, Switzerland.
⁴ Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland; Institute for Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁵ Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg CH-1700, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland. Electronic address: laurent.poirel@unifr.ch.

No abstract available

Conflict of interest statement

We declare no competing interests.

Heteroresistance to cefepime-taniborbactam in metallo-β-lactamase-encoding Enterobacterales.
Abbott C, Satola SW, Weiss DS. Abbott C, et al. Lancet Infect Dis. 2023 Aug;23(8):e277-e278. doi: 10.1016/S1473-3099(23)00426-7. Epub 2023 Jul 5. Lancet Infect Dis. 2023. PMID: 37421967 No abstract available.